OncoMatch/Clinical Trials/NCT06976190
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Is NCT06976190 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including MRG003 + Pucotenlimab and Gemcitabine, Docetaxel, or Capecitabine for recurrent or metastatic nasopharyngeal carcinoma.
Treatment: MRG003 + Pucotenlimab · Gemcitabine, Docetaxel, or Capecitabine — This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: mmae/mmaf adc drugs
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%
No severe cardiac dysfunction, left ventricular ejection fraction (LVEF) ≥50%. Organ functions and coagulation function must meet the basic requirements.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06976190 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mmae/mmaf adc drugs disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages